Becton, Dickinson and Company (BDX)
Chart Events
Performance Outlook
| Previous Close | 240.88 |
| Open | 241.84 |
| Bid | 244.14 x 1100 |
| Ask | 244.38 x 1100 |
| Day's Range | 241.30 - 245.89 |
| 52 Week Range | 197.75 - 284.97 |
| Volume | 520,115 |
| Avg. Volume | 1,299,135 |
| Market Cap | 71.083B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | 46.54 |
| EPS (TTM) | 5.26 |
| Earnings Date | May 05, 2021 - May 10, 2021 |
| Forward Dividend & Yield | 3.32 (1.37%) |
| Ex-Dividend Date | Mar 09, 2021 |
| 1y Target Est | 281.57 |
- PR Newswire
BD Acquires GSL Solutions, Inc., Broadening Medication Management Offerings for Retail, Outpatient Pharmacy Settings
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc. ("GSL"), a privately-held company that develops smart medication devices for the storage and tracking of controlled substances and patient specific medications that improve the security, efficiency and compliance of medication storage, as well as analytic capabilities to further improve inventory management, including of controlled substances, regulatory compliance and patient safety.
- Motley Fool
These 3 Stocks Should Be Big Winners From President Biden's Policy Changes
The new president has a lot of work to do, and many companies are likely to benefit from some of his priorities.
- PR Newswire
BD Announces Collaboration for At-Home Rapid Test for COVID-19
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a collaboration to create an at-home rapid test for SARS-CoV-2 using a BD antigen test and the Scanwell Health mobile app.
